Johnson John

Johnson John is listed in filings as Director at Xeris Biopharma Holdings, Inc.. This profile follows SEC Form 4 activity through Jun 5, 2026, including sale activity. Recent filings connect the profile to Xeris Biopharma Holdings, Inc. (XERS), Verastem, Inc. (VSTM), AxoGen, Inc. (AXGN), and Applied Therapeutics, Inc. (APLT). The current snapshot covers public activity from Jun 20, 2024 to Jun 5, 2026. Reported amounts are shown as $202.9K to $478.0K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.